| Year |
Citation |
Score |
| 2023 |
Harwood OE, Matschke LM, Moriarty RV, Balgeman AJ, Weaver AJ, Ellis-Connell AL, Weiler AM, Winchester LC, Fletcher CV, Friedrich TC, Keele BF, O'Connor DH, Lang JD, Reynolds MR, O'Connor SL. CD8+ cells and small viral reservoirs facilitate post-ART control of SIV replication in M3+ Mauritian cynomolgus macaques initiated on ART two weeks post-infection. Plos Pathogens. 19: e1011676. PMID 37747933 DOI: 10.1371/journal.ppat.1011676 |
0.316 |
|
| 2023 |
Harwood OE, Matschke LM, Moriarty RV, Balgeman AJ, Weaver AJ, Ellis-Connell AL, Weiler AM, Winchester LC, Fletcher CV, Friedrich TC, Keele BF, O'Connor DH, Lang JD, Reynolds MR, O'Connor SL. CD8+ cells and small viral reservoirs facilitate post-ART control of SIV in Mauritian cynomolgus macaques. Biorxiv : the Preprint Server For Biology. PMID 36909458 DOI: 10.1101/2023.03.01.530655 |
0.339 |
|
| 2022 |
Fletcher CV, Kroon E, Schacker T, Pinyakorn S, Chomont N, Chottanapund S, Prueksakaew P, Benjapornpong K, Buranapraditkun S, Phanuphak N, Ananworanich J, Vasan S, Hsu D. Persistent HIV transcription and Variable ARV penetration in lymph nodes during plasma viral suppression. Aids (London, England). PMID 35184069 DOI: 10.1097/QAD.0000000000003201 |
0.324 |
|
| 2022 |
Miller JS, Davis ZB, Helgeson E, Reilly C, Thorkelson A, Anderson J, Lima NS, Jorstad S, Hart GT, Lee JH, Safrit JT, Wong H, Cooley S, Gharu L, Chung H, ... ... Fletcher CV, et al. Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial. Nature Medicine. PMID 35102335 DOI: 10.1038/s41591-021-01651-9 |
0.337 |
|
| 2021 |
Podany AT, Pham M, Sizemore E, Martinson N, Samaneka W, Mohapi L, Badal-Faesen S, Dawson R, Johnson JL, Mayanja H, Lalloo U, Whitworth WC, Pettit A, Campbell K, Phillips P, ... ... Fletcher CV, et al. Efavirenz pharmacokinetics and HIV-1 viral suppression among patients receiving TB treatment containing daily high-dose rifapentine. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 34918028 DOI: 10.1093/cid/ciab1037 |
0.333 |
|
| 2021 |
Kendall MA, Lalloo U, Fletcher CV, Wu X, Podany AT, Cardoso SW, Ive P, Benson CA. Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 73: 706-715. PMID 34398956 DOI: 10.1093/cid/ciab097 |
0.303 |
|
| 2021 |
Dyavar SR, Kumar S, Gautam N, Podany AT, Winchester LC, Weinhold JA, Mykris TM, Nallasamy P, Alnouti Y, Fletcher CV. Intramuscular and subcutaneous administration of antiretroviral drugs, compared with oral, enhances delivery to lymphoid tissues in BALB/c mice. The Journal of Antimicrobial Chemotherapy. PMID 34312680 DOI: 10.1093/jac/dkab228 |
0.327 |
|
| 2021 |
Hoque TMD, Cattin A, Whyte-Allman SK, Winchester L, Fletcher CV, Routy JP, Ancuta P, Bendayan R. Antiretroviral Drug Transporters and Metabolic Enzymes in Circulating Monocytes and Monocyte-Derived Macrophages of ART-Treated People Living With HIV and HIV-Uninfected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999). 87: 1093-1101. PMID 34153016 DOI: 10.1097/QAI.0000000000002682 |
0.351 |
|
| 2021 |
Fletcher CV, Dyavar SR, Acharya A, Byrareddy SN. The Contributions of Clinical Pharmacology to HIV Cure Research. Clinical Pharmacology and Therapeutics. PMID 33763860 DOI: 10.1002/cpt.2237 |
0.386 |
|
| 2021 |
Kendall MA, Lalloo U, Fletcher CV, Wu X, Podany AT, Cardoso SW, Ive P, Benson CA. Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin vs. Lopinavir/Ritonavir + Daily Rifabutin for Treatment of HIV-TB Coinfection. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 33560349 DOI: 10.1093/cid/ciab097 |
0.312 |
|
| 2020 |
Avedissian SN, Dyavar SR, Fox HS, Fletcher CV. Pharmacologic approaches to HIV-associated neurocognitive disorders. Current Opinion in Pharmacology. 54: 102-108. PMID 33049585 DOI: 10.1016/j.coph.2020.09.003 |
0.375 |
|
| 2020 |
Scarsi KK, Havens JP, Podany AT, Avedissian SN, Fletcher CV. HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety. Drugs. PMID 32860583 DOI: 10.1007/s40265-020-01379-9 |
0.368 |
|
| 2020 |
Podany AT, Scarsi KK, Pham MM, Fletcher CV. Comparative Clinical Pharmacokinetics a1 nd Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review. Clinical Pharmacokinetics. PMID 32462541 DOI: 10.1007/s40262-020-00898-8 |
0.382 |
|
| 2020 |
Fletcher CV, Podany AT, Thorkelson A, Winchester LC, Mykris T, Anderson J, Jorstad S, Baker JV, Schacker TW. The Lymphoid Tissue Pharmacokinetics of Tenofovir disoproxil fumarate and Tenofovir alafenamide in HIV-infected Persons. Clinical Pharmacology and Therapeutics. PMID 32385902 DOI: 10.1002/cpt.1883 |
0.398 |
|
| 2020 |
Cirrincione LR, Podany AT, Havens JP, Bares SH, Dyavar SR, Gwon Y, Johnson TM, Amoura NJ, Fletcher CV, Scarsi KK. Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy. The Journal of Antimicrobial Chemotherapy. PMID 32065631 DOI: 10.1093/jac/dkaa016 |
0.332 |
|
| 2020 |
Welch JL, Kaddour H, Winchester L, Fletcher CV, Stapleton JT, Okeoma CM. Semen Extracellular Vesicles From HIV-1-Infected Individuals Inhibit HIV-1 Replication In Vitro, and Extracellular Vesicles Carry Antiretroviral Drugs In Vivo. Journal of Acquired Immune Deficiency Syndromes (1999). 83: 90-98. PMID 31809364 DOI: 10.1097/Qai.0000000000002233 |
0.386 |
|
| 2019 |
Havens JP, Podany AT, Scarsi KK, Fletcher CV. Clinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review. Clinical Pharmacokinetics. PMID 31679131 DOI: 10.1007/s40262-019-00830-9 |
0.382 |
|
| 2019 |
Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, ... ... Fletcher CV, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. The New England Journal of Medicine. 380: 1001-1011. PMID 30865794 DOI: 10.1056/Nejmoa1806808 |
0.358 |
|
| 2018 |
Couturier J, Winchester LC, Suliburk JW, Wilkerson GK, Podany AT, Agarwal N, Xuan Chua CY, Nehete PN, Nehete BP, Grattoni A, Sastry KJ, Fletcher CV, Lake JE, Balasubramanyan A, Lewis DE. Adipocytes impair efficacy of antiretroviral therapy. Antiviral Research. PMID 29630975 DOI: 10.1016/j.antiviral.2018.04.002 |
0.347 |
|
| 2018 |
Gandhi M, Gandhi RT, Stefanescu A, Bosch RJ, Cyktor JC, Horng H, Louie A, Phung N, Eron JJ, Hogg E, Macatangay BJC, Hensel C, Fletcher CV, Mellors JW, McMahon DK, et al. Cumulative Antiretroviral Exposure Measured in Hair Is Not Associated With Measures of HIV Persistence or Inflammation Among Individuals on Suppressive ART. The Journal of Infectious Diseases. PMID 29529230 DOI: 10.1093/Infdis/Jiy011 |
0.369 |
|
| 2017 |
Estes JD, Kityo C, Ssali F, Swainson L, Makamdop KN, Del Prete GQ, Deeks SG, Luciw PA, Chipman JG, Beilman GJ, Hoskuldsson T, Khoruts A, Anderson J, Deleage C, Jasurda J, ... ... Fletcher CV, et al. Defining total-body AIDS-virus burden with implications for curative strategies. Nature Medicine. PMID 28967921 DOI: 10.1038/Nm.4411 |
0.356 |
|
| 2016 |
Sandkovsky U, Podany AT, Fletcher CV, Owen A, Felton-Coleman A, Winchester LC, Robertson K, Swindells S. Impact of efavirenz pharmacokinetics and pharmacogenomics on neuropsychological performance in older HIV-infected patients. The Journal of Antimicrobial Chemotherapy. PMID 27655857 DOI: 10.1093/Jac/Dkw403 |
0.364 |
|
| 2016 |
Podany AT, Scarsi KK, Fletcher CV. Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors. Clinical Pharmacokinetics. PMID 27317415 DOI: 10.1007/s40262-016-0424-1 |
0.427 |
|
| 2016 |
Cressey TR, Yogev R, Wiznia A, Hazra R, Jean-Philippe P, Graham B, Gonzalez A, Britto P, Carey VJ, Fletcher CV, Acosta EP. Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults. Journal of the Pediatric Infectious Diseases Society. PMID 27103489 DOI: 10.1093/Jpids/Piw017 |
0.5 |
|
| 2016 |
Castillo-Mancilla JR, Aquilante CL, Wempe MF, Smeaton LM, Firnhaber C, LaRosa AM, Kumarasamy N, Andrade A, Baheti G, Fletcher CV, Campbell TB, Haas DW, MaWhinney S, Anderson PL. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). The Journal of Antimicrobial Chemotherapy. PMID 26892777 DOI: 10.1093/Jac/Dkw005 |
0.776 |
|
| 2016 |
Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Kosakovsky Pond SL, Chung YS, Penugonda S, Chipman JG, Fletcher CV, Schacker TW, Malim MH, Rambaut A, Haase AT, McLean AR, et al. Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature. PMID 26814962 DOI: 10.1038/Nature16933 |
0.323 |
|
| 2016 |
Bolaris MA, Keller MA, Robbins BL, Podany AT, Fletcher CV. Nevirapine Plasma Concentrations in Human Immunodeficiency Virus-Exposed Neonates Receiving High-Dose Nevirapine Prophylaxis as Part of 3-Drug Regimen. Journal of the Pediatric Infectious Diseases Society. PMID 26803329 DOI: 10.1093/jpids/piv084 |
0.314 |
|
| 2015 |
Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, Supparatpinyo K, Mohapi L, Gupta A, Benson CA, Kim P, Fletcher CV. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 26082504 DOI: 10.1093/Cid/Civ464 |
0.381 |
|
| 2015 |
Rothenberger MK, Keele BF, Wietgrefe SW, Fletcher CV, Beilman GJ, Chipman JG, Khoruts A, Estes JD, Anderson J, Callisto SP, Schmidt TE, Thorkelson A, Reilly C, Perkey K, Reimann TG, et al. Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proceedings of the National Academy of Sciences of the United States of America. 112: E1126-34. PMID 25713386 DOI: 10.1073/Pnas.1414926112 |
0.335 |
|
| 2015 |
Rutstein RM, Samson P, Fenton T, Fletcher CV, Kiser JJ, Mofenson LM, Smith E, Graham B, Mathew M, Aldrovani G. Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A. The Pediatric Infectious Disease Journal. 34: 162-7. PMID 25232777 DOI: 10.1097/INF.0000000000000538 |
0.347 |
|
| 2014 |
Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, Beilman GJ, Khoruts A, Thorkelson A, Schmidt TE, Anderson J, Perkey K, Stevenson M, Perelson AS, Douek DC, et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proceedings of the National Academy of Sciences of the United States of America. 111: 2307-12. PMID 24469825 DOI: 10.1073/Pnas.1318249111 |
0.342 |
|
| 2014 |
Salem AH, Fletcher CV, Brundage RC. Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children. Antimicrobial Agents and Chemotherapy. 58: 136-43. PMID 24145522 DOI: 10.1128/Aac.01738-13 |
0.337 |
|
| 2013 |
Cory TJ, Schacker TW, Stevenson M, Fletcher CV. Overcoming pharmacologic sanctuaries. Current Opinion in Hiv and Aids. 8: 190-5. PMID 23454865 DOI: 10.1097/Coh.0B013E32835Fc68A |
0.389 |
|
| 2013 |
Baheti G, King JR, Acosta EP, Fletcher CV. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults. Aids (London, England). 27: 221-5. PMID 23032419 DOI: 10.1097/Qad.0B013E32835A9A2D |
0.751 |
|
| 2012 |
Sandkovsky U, Swindells S, Robbins BL, Nelson SR, Acosta EP, Fletcher CV. Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection. Aids (London, England). 26: 2257-9. PMID 22948265 DOI: 10.1097/Qad.0B013E328359A978 |
0.582 |
|
| 2012 |
Sandkovsky U, Swindells S, Moore R, Acosta EP, Fletcher CV. Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection. Pharmacotherapy. 32: 142-7. PMID 22392423 DOI: 10.1002/Phar.1015 |
0.569 |
|
| 2011 |
Baheti G, Kiser JJ, Havens PL, Fletcher CV. Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Antimicrobial Agents and Chemotherapy. 55: 5294-9. PMID 21896913 DOI: 10.1128/Aac.05317-11 |
0.756 |
|
| 2011 |
Umeh OC, Currier JS, Park JG, Cramer Y, Hermes AE, Fletcher CV. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. Journal of Clinical Pharmacology. 51: 1665-73. PMID 21233301 DOI: 10.1177/0091270010388650 |
0.377 |
|
| 2010 |
Fletcher CV. Drug interactions should be evaluated in patients. Clinical Pharmacology and Therapeutics. 88: 585-7. PMID 20959842 DOI: 10.1038/Clpt.2010.213 |
0.325 |
|
| 2010 |
Van Schooneveld T, Swindells S, Nelson SR, Robbins BL, Moore R, Fletcher CV. Clinical evaluation of a dried blood spot assay for atazanavir. Antimicrobial Agents and Chemotherapy. 54: 4124-8. PMID 20660680 DOI: 10.1128/AAC.00297-10 |
0.35 |
|
| 2009 |
Delahunty T, Bushman L, Robbins B, Fletcher CV. The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 877: 1907-14. PMID 19493710 DOI: 10.1016/J.Jchromb.2009.05.029 |
0.366 |
|
| 2009 |
Fletcher CV. Antiretroviral drug-drug interaction considerations for HIV-infected children. The Pediatric Infectious Disease Journal. 28: 429-30. PMID 19395949 DOI: 10.1097/Inf.0B013E3181A622Bb |
0.449 |
|
| 2008 |
Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne FM, Huebner RE, Janoff EN, Justice AC, Kuritzkes D, Nayfield SG, Plaeger SF, Schmader KE, Ashworth JR, Campanelli C, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 47: 542-53. PMID 18627268 DOI: 10.1086/590150 |
0.449 |
|
| 2008 |
Torno MS, Witt MD, Saitoh A, Fletcher CV. Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature. Pharmacotherapy. 28: 782-7. PMID 18503405 DOI: 10.1592/phco.28.6.782 |
0.386 |
|
| 2008 |
Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes (1999). 47: 298-303. PMID 18398970 DOI: 10.1097/QAI.0b013e31815e7478 |
0.343 |
|
| 2008 |
Kiser JJ, Fletcher CV, Flynn PM, Cunningham CK, Wilson CM, Kapogiannis BG, Major-Wilson H, Viani RM, Liu NX, Muenz LR, Harris DR, Havens PL, Puga A, Leonard E, Eysallenne Z, et al. Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection Antimicrobial Agents and Chemotherapy. 52: 631-637. PMID 18025112 DOI: 10.1128/Aac.00761-07 |
0.34 |
|
| 2008 |
Fletcher CV, Brundage RC, Fenton T, Alvero CG, Powell C, Mofenson LM, Spector SA. Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial Clinical Pharmacology and Therapeutics. 83: 300-306. PMID 17609682 DOI: 10.1038/Sj.Clpt.6100282 |
0.468 |
|
| 2008 |
Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahunty T, Bushman LR, Fletcher CV. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clinical Pharmacology and Therapeutics. 83: 265-72. PMID 17597712 DOI: 10.1038/Sj.Clpt.6100269 |
0.353 |
|
| 2007 |
Ndovi TT, Cao YJ, Fuchs E, Fletcher CV, Guidos A, Hendrix CW. Food affects Zidovudine concentration independent of effects on gastrointestinal absorption. Journal of Clinical Pharmacology. 47: 1366-73. PMID 17962425 DOI: 10.1177/0091270007306562 |
0.318 |
|
| 2007 |
Saitoh A, Fenton T, Alvero C, Fletcher CV, Spector SA. Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy Antimicrobial Agents and Chemotherapy. 51: 4236-4242. PMID 17893156 DOI: 10.1128/AAC.00893-07 |
0.331 |
|
| 2007 |
Margolis DM, Mukherjee AL, Fletcher CV, Hogg E, Ogata-Arakaki D, Petersen T, Rusin D, Martinez A, Mellors JW. The use of β-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection Aids. 21: 2025-2032. PMID 17885292 DOI: 10.1097/Qad.0B013E3282364381 |
0.357 |
|
| 2007 |
Fletcher CV. Translating efficacy into effectiveness in antiretroviral therapy: beyond the pill count. Drugs. 67: 1969-79. PMID 17883282 DOI: 10.2165/00003495-200767140-00001 |
0.502 |
|
| 2007 |
Anderson PL, Zheng JH, King T, Bushman LR, Predhomme J, Meditz A, Gerber J, Fletcher CV. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults. Aids (London, England). 21: 1849-54. PMID 17721092 DOI: 10.1097/QAD.0b013e3282741feb |
0.342 |
|
| 2007 |
Saitoh A, Fletcher CV, Brundage R, Alvero C, Fenton T, Hsia K, Spector SA. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. Journal of Acquired Immune Deficiency Syndromes (1999). 45: 280-5. PMID 17356468 DOI: 10.1097/Qai.0B013E318040B29E |
0.32 |
|
| 2007 |
Fletcher CV, DeVille JG, Samson PM, Moye JH, Church JA, Spiegel HM, Palumbo P, Fenton T, Smith ME, Graham B, Kraimer JM, Shearer WT. Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children. The Journal of Allergy and Clinical Immunology. 119: 747-50. PMID 17336619 DOI: 10.1016/J.Jaci.2006.10.045 |
0.408 |
|
| 2006 |
Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, Godfrey C, Bastow B, Ray MG, Wang H, Coombs RW, McKinnon J, Mellors JW. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. Jama. 296: 806-14. PMID 16905786 DOI: 10.1001/Jama.296.7.806 |
0.332 |
|
| 2006 |
Shearer WT, DeVille JG, Samson PM, Moye JH, Fletcher CV, Church JA, Spiegel HM, Palumbo P, Fenton T, Smith ME, Graham B, Kraimer JM, Olson WC. Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140). The Journal of Allergy and Clinical Immunology. 118: 518-21. PMID 16890780 DOI: 10.1016/J.Jaci.2006.03.028 |
0.359 |
|
| 2006 |
Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. Journal of Acquired Immune Deficiency Syndromes (1999). 42: 441-9. PMID 16791115 DOI: 10.1097/01.Qai.0000225013.53568.69 |
0.449 |
|
| 2006 |
Saitoh A, Singh KK, Sandall S, Powell CA, Fenton T, Fletcher CV, Hsia K, Spector SA. Association of CD4 + T-lymphocyte counts and new thymic emigrants in HIV-infected children during successful highly active antiretroviral therapy Journal of Allergy and Clinical Immunology. 117: 909-915. PMID 16630951 DOI: 10.1016/J.Jaci.2006.01.013 |
0.311 |
|
| 2006 |
Kiser JJ, Lichtenstein KA, Anderson PL, Fletcher CV. Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection. Pharmacotherapy. 26: 511-4. PMID 16553510 DOI: 10.1592/phco.26.4.511 |
0.421 |
|
| 2006 |
Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford DB, Marzolini C, Fletcher CV, Tashima KT, Kuritzkes DR, Acosta EP. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 42: 401-7. PMID 16392089 DOI: 10.1086/499364 |
0.541 |
|
| 2006 |
Shearer W, Deville J, Samson P, MoyeJr. J, Fletcher C, Church J, Spiegel H, Palumbo P, Fenton T, Smith E, Graham B, Kraimer J, Olson W. Sa.75. Susceptibility of Viral Isolates of Pediatric AIDS Clinical Trials Group Protocol 351 to Pro 542 (Rcd4-Igg2) and Pro 140 (Mab to Ccr5) Clinical Immunology. 119: S131. DOI: 10.1016/J.Clim.2006.04.307 |
0.311 |
|
| 2005 |
Fletcher CV, Testa MA, Brundage RC, Chesney MA, Haubrich R, Acosta EP, Martinez A, Jiang H, Gulick RM. Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. Journal of Acquired Immune Deficiency Syndromes (1999). 40: 301-6. PMID 16249704 DOI: 10.1097/01.Qai.0000180078.53321.6A |
0.587 |
|
| 2005 |
Boffito M, Acosta E, Burger D, Fletcher CV, Flexner C, Garaffo R, Gatti G, Kurowski M, Perno CF, Peytavin G, Regazzi M, Back D. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antiviral Therapy. 10: 469-77. PMID 16038472 |
0.559 |
|
| 2005 |
Campbell TB, Shulman NS, Johnson SC, Zolopa AR, Young RK, Bushman L, Fletcher CV, Lanier ER, Merigan TC, Kuritzkes DR. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 41: 236-42. PMID 15983922 DOI: 10.1086/430709 |
0.322 |
|
| 2005 |
King JR, Gerber JG, Fletcher CV, Bushman L, Acosta EP. Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy. Aids (London, England). 19: 1059-63. PMID 15958837 DOI: 10.1097/01.Aids.0000174452.78497.54 |
0.504 |
|
| 2005 |
Boffito M, Acosta E, Burger D, Fletcher CV, Flexner C, Garaffo R, Gatti G, Kurowski M, Perno CF, Peytavin G, Regazzi M, Back D. Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antiviral Therapy. 10: 375-92. PMID 15918329 |
0.577 |
|
| 2005 |
Pelton SI, Stanley K, Yogev R, Fletcher CV, McIntosh K, Wiznia A, Nachman S. Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 40: 1181-7. PMID 15791520 DOI: 10.1086/428833 |
0.481 |
|
| 2005 |
Saitoh A, Singh KK, Powell CA, Fenton T, Fletcher CV, Brundage R, Starr S, Spector SA. An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. Aids (London, England). 19: 371-80. PMID 15750390 DOI: 10.1097/01.Aids.0000161766.13782.2F |
0.417 |
|
| 2004 |
Anderson PL, Fletcher CV. Updated clinical pharmacologic considerations for HIV-1 protease inhibitors. Current Hiv/Aids Reports. 1: 33-9. PMID 16091221 |
0.351 |
|
| 2004 |
Swanstrom R, Bosch RJ, Katzenstein D, Cheng H, Jiang H, Hellmann N, Haubrich R, Fiscus SA, Fletcher CV, Acosta EP, Gulick RM. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. The Journal of Infectious Diseases. 190: 886-93. PMID 15295692 DOI: 10.1086/422692 |
0.645 |
|
| 2004 |
Fletcher CV, Yogev R, Nachman SA, Wiznia A, Pelton S, McIntosh K, Stanley K. Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection. Pharmacotherapy. 24: 453-9. PMID 15098798 DOI: 10.1592/Phco.24.5.453.33343 |
0.448 |
|
| 2004 |
Fletcher CV. Antiretroviral therapy for HIV-infected infants: progress and pitfalls. Aids (London, England). 18: 325-6. PMID 15075552 DOI: 10.1097/00002030-200401230-00024 |
0.421 |
|
| 2004 |
Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, Gulick RM. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. The Journal of Infectious Diseases. 189: 1176-84. PMID 15031785 DOI: 10.1086/382754 |
0.569 |
|
| 2004 |
Brundage RC, Yong FH, Fenton T, Spector SA, Starr SE, Fletcher CV. Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy. Antimicrobial Agents and Chemotherapy. 48: 979-84. PMID 14982792 DOI: 10.1128/Aac.48.3.979-984.2004 |
0.421 |
|
| 2003 |
Hoody DW, Fletcher CV. Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children. Seminars in Pediatric Infectious Diseases. 14: 286-94. PMID 14724793 |
0.383 |
|
| 2003 |
Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals Aids. 17: 2159-2168. PMID 14523272 DOI: 10.1097/00002030-200310170-00003 |
0.391 |
|
| 2003 |
Fletcher CV. Enfuvirtide, a new drug for HIV infection. Lancet (London, England). 361: 1577-8. PMID 12747873 DOI: 10.1016/S0140-6736(03)13323-5 |
0.478 |
|
| 2002 |
Starr SE, Fletcher CV, Spector SA, Brundage RC, Yong FH, Douglas SD, Flynn PM, Kline MW. Efavirenz liquid formulation in human immunodeficiency virus-infected children. The Pediatric Infectious Disease Journal. 21: 659-63. PMID 12237599 DOI: 10.1097/00006454-200207000-00011 |
0.398 |
|
| 2002 |
Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D. Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. The Journal of Infectious Diseases. 186: 626-33. PMID 12195349 DOI: 10.1086/342681 |
0.619 |
|
| 2002 |
Wynn HE, Brundage RC, Fletcher CV. Clinical implications of CNS penetration of antiretroviral drugs. Cns Drugs. 16: 595-609. PMID 12153332 DOI: 10.2165/00023210-200216090-00002 |
0.497 |
|
| 2002 |
Guay LA, Musoke P, Hom DL, Nakabiito C, Bagenda D, Fletcher CV, Marum LH, Fowler MG, Falksveden LG, Wahren B, Kataaha P, Wigzell H, Mmiro FA, Brooks Jackson J. Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda Aids. 16: 1391-1400. PMID 12131216 DOI: 10.1097/00002030-200207050-00011 |
0.32 |
|
| 2002 |
Back D, Gatti G, Fletcher C, Garaffo R, Haubrich R, Hoetelmans R, Kurowski M, Luber A, Merry C, Perno CF. Therapeutic drug monitoring in HIV infection: current status and future directions. Aids (London, England). S5-37. PMID 12035820 DOI: 10.1097/00002030-200203001-00002 |
0.353 |
|
| 2002 |
Saitoh A, Hsia K, Fenton T, Powell CA, Christopherson C, Fletcher CV, Starr SE, Spector SA. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. The Journal of Infectious Diseases. 185: 1409-16. PMID 11992275 DOI: 10.1086/340614 |
0.456 |
|
| 2002 |
Anderson PL, Brundage RC, Kakuda TN, Fletcher CV. CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid. Clinical Pharmacology and Therapeutics. 71: 280-5. PMID 11956511 DOI: 10.1067/Mcp.2002.121910 |
0.368 |
|
| 2002 |
Fletcher CV, Anderson PL, Kakuda TN, Schacker TW, Henry K, Gross CR, Brundage RC. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. Aids (London, England). 16: 551-60. PMID 11872998 DOI: 10.1097/00002030-200203080-00006 |
0.506 |
|
| 2001 |
Anderson PL, Fletcher CV. Clinical Pharmacologic Considerations for HIV-1 Protease Inhibitors. Current Infectious Disease Reports. 3: 381-387. PMID 11470030 DOI: 10.1007/S11908-001-0079-3 |
0.49 |
|
| 2001 |
Kline MW, Brundage RC, Fletcher CV, Schwarzwald H, Calles NR, Buss NE, Snell P, DeLora P, Eason M, Jorga K, Craig C, Duff F. Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection. The Pediatric Infectious Disease Journal. 20: 666-71. PMID 11465838 DOI: 10.1097/00006454-200107000-00006 |
0.48 |
|
| 2001 |
Kakuda TN, Page LM, Anderson PL, Henry K, Schacker TW, Rhame FS, Acosta EP, Brundage RC, Fletcher CV. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir Antimicrobial Agents and Chemotherapy. 45: 236-242. PMID 11120972 DOI: 10.1128/Aac.45.1.236-242.2001 |
0.595 |
|
| 2000 |
Fletcher CV, Acosta EP, Cheng H, Haubrich R, Fischl M, Raasch R, Mills C, Hu XJ, Katzenstein D, Remmel RP, Gulick RM. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884 Aids. 14: 2495-2501. PMID 11101060 DOI: 10.1097/00002030-200011100-00011 |
0.618 |
|
| 2000 |
Anderson PL, Brundage RC, Bushman L, Kakuda TN, Remmel RP, Fletcher CV. Indinavir plasma protein binding in HIV-1-infected adults Aids. 14: 2293-2297. PMID 11089617 DOI: 10.1097/00002030-200010200-00010 |
0.507 |
|
| 2000 |
Shearer WT, Israel RJ, Starr S, Fletcher CV, Wara D, Rathore M, Church J, DeVille J, Fenton T, Graham B, Samson P, Staprans S, McNamara J, Moye J, Maddon PJ, et al. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: Phase 1/2 study Journal of Infectious Diseases. 182: 1774-1779. PMID 11069253 DOI: 10.1086/317622 |
0.481 |
|
| 2000 |
Spector SA, Hsia K, Yong FH, Cabral S, Fenton T, Fletcher CV, McNamara J, Mofenson LM, Starr SE. Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children. The Journal of Infectious Diseases. 182: 1769-73. PMID 11069252 DOI: 10.1086/317621 |
0.478 |
|
| 2000 |
Fletcher CV, Kawle SP, Kakuda TN, Anderson PL, Weller D, Bushman LR, Brundage RC, Remmel RP. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons Aids. 14: 2137-2144. PMID 11061655 DOI: 10.1097/00002030-200009290-00010 |
0.492 |
|
| 2000 |
Haas DW, Clough LA, Johnson BW, Harris VL, Spearman P, Wilkinson GR, Fletcher CV, Fiscus S, Raffanti S, Donlon R, McKinsey J, Nicotera J, Schmidt D, Shoup RE, Kates RE, et al. Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. Aids Research and Human Retroviruses. 16: 1491-502. PMID 11054262 DOI: 10.1089/088922200750006010 |
0.455 |
|
| 2000 |
Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group study 359 Journal of Infectious Diseases. 182: 1375-1384. PMID 11023461 DOI: 10.1086/315867 |
0.641 |
|
| 2000 |
Leflore S, Anderson PL, Fletcher CV. A risk-benefit evaluation of aciclovir for the treatment and prophylaxis of herpes simplex virus infections. Drug Safety. 23: 131-42. PMID 10945375 DOI: 10.2165/00002018-200023020-00004 |
0.355 |
|
| 2000 |
Anderson PL, Noormohamed SE, Henry K, Brundage RC, Balfour HH, Fletcher CV. Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection. Pharmacotherapy. 20: 917-22. PMID 10939552 DOI: 10.1592/Phco.20.11.917.35263 |
0.377 |
|
| 2000 |
Jacobson JM, Lowy I, Fletcher CV, Neill TJ, Tran DNH, Ketas TJ, Trkola A, Klotman ME, Maddon PJ, Olson WC, Israel RJ. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults Journal of Infectious Diseases. 182: 326-329. PMID 10882617 DOI: 10.1086/315698 |
0.483 |
|
| 2000 |
Acosta EP, Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors Clinical Infectious Diseases. 30. PMID 10860900 DOI: 10.1086/313852 |
0.611 |
|
| 2000 |
Fletcher CV, Brundage RC, Remmel RP, Page LM, Weller D, Calles NR, Simon C, Kline MW. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrobial Agents and Chemotherapy. 44: 1029-34. PMID 10722507 DOI: 10.1128/Aac.44.4.1029-1034.2000 |
0.493 |
|
| 2000 |
Stiehm ER, Fletcher CV, Mofenson LM, Palumbo PE, Kang M, Fenton T, Sapan CV, Meyer WA, Shearer WT, Hawkins E, Fowler MG, Bouquin P, Purdue L, Sloand EM, Nemo GJ, et al. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). The Journal of Infectious Diseases. 181: 548-54. PMID 10669338 DOI: 10.1086/315224 |
0.501 |
|
| 2000 |
Remmel RP, Kawle SP, Weller D, Fletcher CV. Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma Clinical Chemistry. 46: 73-81. PMID 10620574 DOI: 10.1093/Clinchem/46.1.73 |
0.45 |
|
| 1999 |
Starr SE, Fletcher CV, Spector SA, Yong FH, Fenton T, Brundage RC, Manion D, Ruiz N, Gersten M, Becker M, McNamara J, Mofenson LM, Purdue L, Siminski S, Graham B, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. The New England Journal of Medicine. 341: 1874-81. PMID 10601506 DOI: 10.1056/Nejm199912163412502 |
0.315 |
|
| 1999 |
Fletcher CV. Pharmacologic considerations for therapeutic success with antiretroviral agents. The Annals of Pharmacotherapy. 33: 989-95. PMID 10492504 DOI: 10.1345/Aph.19075 |
0.426 |
|
| 1999 |
Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy. 19: 708-12. PMID 10391416 DOI: 10.1592/Phco.19.9.708.31544 |
0.558 |
|
| 1999 |
Kline MW, Blanchard S, Fletcher CV, Shenep JL, McKinney RE, Brundage RC, Culnane M, Van Dyke RB, Dankner WM, Kovacs A, McDowell JA, Hetherington S. A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team. Pediatrics. 103: e47. PMID 10103339 DOI: 10.1542/peds.103.4.e47 |
0.346 |
|
| 1999 |
Stiehm ER, Fletcher C, Mofenson LM. Human Hyperimmune HIV Intravenous Immunoglobulin (HIV-IG) in the Treatment of HIV-1 Infection in Children (PACTG-273) Pediatric Research. 45: 175A-175A. DOI: 10.1203/00006450-199904020-01041 |
0.358 |
|
| 1999 |
Fletcher CV, Kakuda TN, Page LM, Acosta EP, Brundage RC, Anderson PL, Henry K, Schacker T. Pharmacokinetic strategies for concentration-targeted therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV) Clinical Pharmacology and Therapeutics. 65: 161. DOI: 10.1016/S0009-9236(99)80174-X |
0.54 |
|
| 1998 |
Kakuda TN, Acosta EP, Fletcher CV. Potential confusion with antiretroviral drugs American Journal of Health-System Pharmacy. 55: 2639-2640. PMID 9872703 DOI: 10.1093/Ajhp/55.24.2639 |
0.546 |
|
| 1998 |
Fletcher CV, Acosta EP, Henry K, Page LM, Gross CR, Kawle SP, Remmel RP, Erice A, Balfour HH. Concentration-controlled zidovudine therapy. Clinical Pharmacology and Therapeutics. 64: 331-8. PMID 9757157 DOI: 10.1016/S0009-9236(98)90182-5 |
0.668 |
|
| 1998 |
Kline MW, Fletcher CV, Harris AT, Evans KD, Brundage RC, Remmel RP, Calles NR, Kirkpatrick SB, Simon C. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. The Journal of Pediatrics. 132: 543-6. PMID 9544920 DOI: 10.1016/S0022-3476(98)70039-3 |
0.308 |
|
| 1997 |
Fletcher CV, Goodroad BK, Cummins LM, Henry K, Balfour HH, Rhame FS. Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS. Antimicrobial Agents and Chemotherapy. 41: 1571-4. PMID 9210687 DOI: 10.1128/Aac.41.7.1571 |
0.387 |
|
| 1997 |
Lambert JS, Mofenson LM, Fletcher CV, Moye J, Stiehm ER, Meyer WA, Nemo GJ, Mathieson BJ, Hirsch G, Sapan CV, Cummins LM, Jimenez E, O'Neill E, Kovacs A, Stek A. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. The Journal of Infectious Diseases. 175: 283-91. PMID 9203648 DOI: 10.1093/INFDIS/175.2.283 |
0.375 |
|
| 1997 |
Fletcher CV. Pharmacologic considerations for antiviral drug development. The Annals of Pharmacotherapy. 30: 972-7. PMID 8876859 DOI: 10.1177/106002809603000912 |
0.304 |
|
| 1997 |
Kline MW, Fletcher CV, Harris AT, Brundage RC, Evans KD, Simon C, Bohannon B, Calles NR, Shearer WT. Combination Therapy with Stavudine (d4T), Didanosine (ddI), and Indinavir in HIV-Infected Children • 727 Pediatric Research. 41: 124-124. DOI: 10.1203/00006450-199704001-00747 |
0.346 |
|
| 1997 |
Acosta EP, Henry K, Page LM, Erice A, Balfour HH, Fletcher CV. Pharmacokinetics and safety of concentration-controlled oral zidovudine therapy. Pharmacotherapy. 17: 424-430. DOI: 10.1002/J.1875-9114.1997.Tb03052.X |
0.576 |
|
| 1996 |
Balfour HH, Fletcher CV, Erice A, Henry WK, Acosta EP, Smith SA, Holm MA, Boivin G, Shepp DH, Crumpacker CS, Eaton CA, Martin-Munley SS. Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. Antimicrobial Agents and Chemotherapy. 40: 2721-6. PMID 9124829 DOI: 10.1128/Aac.40.12.2721 |
0.654 |
|
| 1996 |
Acosta EP, Page LM, Fletcher CV. Clinical pharmacokinetics of zidovudine. An update. Clinical Pharmacokinetics. 30: 251-62. PMID 8983858 DOI: 10.2165/00003088-199630040-00001 |
0.635 |
|
| 1996 |
Acosta EP, Schwebke K, Henry K, Fletcher CV. Disposition of zidovudine in obese pregnant women with human immunodeficiency virus type 1 infection. The Journal of Infectious Diseases. 174: 673. PMID 8769638 DOI: 10.1093/Infdis/174.3.673 |
0.529 |
|
| 1996 |
Kline MW, Fletcher CV, Federici ME, Harris AT, Evans KD, Rutkiewicz VL, Shearer WT, Dunkle LM. Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects. Pediatrics. 97: 886-90. PMID 8657531 |
0.332 |
|
| 1996 |
Kline MW, Fletcher CV, Federici ME, Harris AT, Evans KD, Rutkiewicz VL, Shearer WT, Dunkle LM. COMBINATION THERAPY WITH STAVUDINE (D4T) AND DIDANOSINE (DDI) IN CHILDREN WITH ADVANCED HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION. • 1039 Pediatric Research. 39: 176-176. DOI: 10.1203/00006450-199604001-01061 |
0.467 |
|
| 1996 |
Fletcher CV, Balfour HH. Variability in zidovudine serum concentrations Pharmacotherapy. 16: 1154-1158. DOI: 10.1002/J.1875-9114.1996.Tb03044.X |
0.387 |
|
| 1995 |
Acosta EP, Fletcher CV. Antiretroviral drug interactions. International Journal of Antimicrobial Agents. 5: 73-83. PMID 18611653 DOI: 10.1016/0924-8579(94)00063-Z |
0.627 |
|
| 1995 |
Noormohamed SE, Henry WK, Rhame FS, Balfour HH, Fletcher CV. Strategies for control of zidovudine concentrations in serum. Antimicrobial Agents and Chemotherapy. 39: 2792-7. PMID 8593022 DOI: 10.1128/Aac.39.12.2792 |
0.357 |
|
| 1995 |
Schwebke K, Fletcher CV, Acosta EP, Henry K. Pentamidine concentrations in a mother with AIDS and in her neonate. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 20: 1569-70. PMID 7548518 DOI: 10.1093/Clinids/20.6.1569 |
0.489 |
|
| 1995 |
Acosta EP, Fletcher CV. Antiretroviral drug interactions International Journal of Antimicrobial Agents. 5: 73-83. DOI: 10.1016/0924-8579(94)00063-Z |
0.594 |
|
| 1995 |
Fletcher CV, Henry WK, Noormohamed SE, Rhame FS, Balfour HH. The Effect of Cimetidine and Ranitidine Administration With Zidovudine Pharmacotherapy. 15: 701-708. DOI: 10.1002/J.1875-9114.1995.Tb02885.X |
0.4 |
|
| 1994 |
Fletcher CV, Collier AC, Rhame FS, Bennett D, Para MF, Beatty CC, Jones CE, Balfour HH. Foscarnet for suppression of human immunodeficiency virus replication. Antimicrobial Agents and Chemotherapy. 38: 604-7. PMID 7911290 DOI: 10.1128/Aac.38.3.604 |
0.489 |
|
| 1994 |
Acosta EP, Fletcher CV. Agents for treating human immunodeficiency virus infection American Journal of Hospital Pharmacy. 51. PMID 7801986 |
0.332 |
|
| 1994 |
Fletcher CV, Acosta EP, Strykowski JM. Gender differences in human pharmacokinetics and pharmacodynamics. The Journal of Adolescent Health : Official Publication of the Society For Adolescent Medicine. 15: 619-29. PMID 7696281 DOI: 10.1016/S1054-139X(94)90628-9 |
0.531 |
|
| 1994 |
Acosta EP, Fletcher CV. Agents for treating human immunodeficiency virus infection American Journal of Health-System Pharmacy. 51: 2251-2267. DOI: 10.1093/Ajhp/51.18.2251 |
0.62 |
|
| 1993 |
Goodwin SD, Fletcher CV, Drew RH. Pharmacotherapy of disseminated histoplasmosis in patients with AIDS Annals of Pharmacotherapy. 27: 1510-1518. PMID 8305787 DOI: 10.1177/106002809302701218 |
0.42 |
|
| 1993 |
Fletcher CV. Current perspectives on antiretroviral therapy. Pharmacotherapy. 13: 627-33. PMID 7508101 DOI: 10.1002/J.1875-9114.1993.Tb02770.X |
0.514 |
|
| 1993 |
Fletcher CV, Acosta EP. Advances in pharmacotherapy: treatment of HIV infection Journal of Clinical Pharmacy and Therapeutics. 18: 375-388. DOI: 10.1111/J.1365-2710.1993.Tb00875.X |
0.66 |
|
| 1992 |
Goodwin SD, Fletcher CV. Introduction to the "HIV and AIDS" column. The Annals of Pharmacotherapy. 26: 700. PMID 1591434 DOI: 10.1177/106002809202600518 |
0.425 |
|
| 1992 |
Fletcher CV, Rhame FS, Beatty CC, Simpson M, Balfour HH. Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease Pharmacotherapy. 12: 429-434. PMID 1492005 DOI: 10.1002/J.1875-9114.1992.Tb04484.X |
0.432 |
|
| 1992 |
Fletcher CV. Treatment of herpesvirus infections in HIV-infected individuals. The Annals of Pharmacotherapy. 26: 955-62. PMID 1324033 DOI: 10.1177/106002809202600720 |
0.432 |
|
| 1991 |
Dunn DL, Mayoral JL, Gillingham KJ, Loeffler CM, Brayman KL, Kramer MA, Erice A, Balfour HH, Fletcher CV, Bolman RM. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation. 51: 98-106. PMID 1846255 DOI: 10.1097/00007890-199101000-00015 |
0.307 |
|
| 1989 |
Cleary JD, Weisdorf D, Fletcher CV. Effect of infusion rate on amphotericin B-associated febrile reactions. Drug Intelligence & Clinical Pharmacy. 22: 769-72. PMID 3068038 DOI: 10.1177/106002808802201005 |
0.313 |
|
| 1989 |
Fletcher CV, Englund JA, Bean B, Chinnock B, Brundage DM, Balfour HH. Continuous infusion of high-dose acyclovir for serious herpesvirus infections. Antimicrobial Agents and Chemotherapy. 33: 1375-8. PMID 2552909 DOI: 10.1128/Aac.33.8.1375 |
0.384 |
|
| 1988 |
Fletcher CV, Chinnock BJ, Chace B, Balfour HH. Pharmacokinetics and safety of high-dose oral acyclovir for suppression of cytomegalovirus disease after renal transplantation Clinical Pharmacology and Therapeutics. 44: 158-163. PMID 2840229 DOI: 10.1038/Clpt.1988.131 |
0.313 |
|
| 1987 |
Henry K, Cantrill H, Fletcher C, Chinnock BJ, Balfour HH. Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. American Journal of Ophthalmology. 103: 17-23. PMID 3026186 DOI: 10.1016/S0002-9394(14)74163-7 |
0.314 |
|
| 1987 |
Bean B, Fletcher C, Englund J, Lehrman SN, Ellis MN. Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy. Diagnostic Microbiology and Infectious Disease. 7: 199-204. PMID 2820649 DOI: 10.1016/0732-8893(87)90005-8 |
0.362 |
|
| 1986 |
Fletcher C, Sawchuk R, Chinnock B, de Miranda P, Balfour HH. Human pharmacokinetics of the antiviral drug DHPG. Clinical Pharmacology and Therapeutics. 40: 281-6. PMID 3017630 DOI: 10.1038/Clpt.1986.177 |
0.38 |
|
| 1986 |
Fletcher CV, Giese RM, Rodman JH. Pharmacist interventions to improve prescribing of vancomycin and tobramycin American Journal of Health-System Pharmacy. 43: 2198-2201. DOI: 10.1093/Ajhp/43.9.2198 |
0.307 |
|
| Show low-probability matches. |
